Journal of Okayama Medical Association
Published by Okayama Medical Association

Full-text articles are available 3 years after publication.

癌化学療法による宿主造血能抑制の防止に関する基礎的研究 第1編Bestatin[3-(R)-amino-2-(S)-hydroxy-4-phenylbutanoyl-(S)-leucine]のcyclophosphamide誘発造血抑制からの回復促進効果

内田 耕三郎 岡山大学医学部第2内科
99_623.pdf 1.79 MB
The hemopoietic potential of Bestatin, a new immunomodulator prepared from the culture medium of Streptomyces olivoreticuli, was studied concerning its effects on the recovery from cyclophosphamide(CPA)-induced myelosuppression and on autologous CFUs in irradiated mice. In mice treated with CPA (300 mg/kg, i.p., day 0), the recovery from granulocytopenia and myelosuppression was significantly accelerated by administration of Bestatin (0.05 mg/kg, i.p., -day 5 to -day 1). Bestatin, administrated i.p. at a dose of 0.05 mg/kg on -day 1, increased the number of autologous CFUs in irradiated mice, indicating that Bestatin acted at the level of multipotent stem cells. These result indicate that Bestatin may be useful in the clinical management of myelosuppression induced not only by cancer chemotherapy but also by radiation therapy.
Myelosuppression by cancer chemotherapy
Hemopoietic potential of Bestatin